Monday, November 30, 2015

JAMA - "Panretinal Photocoagulation vs Intravitreous Ranibizumab for Proliferative Diabetic Retinopathy"

"Panretinal Photocoagulation vs Intravitreous Ranibizumab for Proliferative Diabetic Retinopathy"

"Conclusions and Relevance  Among eyes with proliferative diabetic retinopathy, treatment with ranibizumab resulted in visual acuity that was noninferior to (not worse than) PRP treatment at 2 years. Although longer-term follow-up is needed, ranibizumab may be a reasonable treatment alternative, at least through 2 years, for patients with proliferative diabetic retinopathy."  

http://jama.jamanetwork.com/article.aspx?articleid=2469891

Thursday, November 26, 2015

CIRC - "Efficacy and Safety of Vorapaxar With and Without a Thienopyridine for Secondary Prevention in Patients With Previous Myocardial Infarction and No History of Stroke or Transient Ischemic Attack"

"Efficacy and Safety of Vorapaxar With and Without a Thienopyridine for Secondary Prevention in Patients With Previous Myocardial Infarction and No History of Stroke or Transient Ischemic Attack"

"Conclusions—Vorapaxar reduced cardiovascular death, MI, or stroke in stable patients with a history of previous MI, whether treated concomitantly with a thienopyridine or not. The relative risk of moderate or severe bleeding was similarly increased irrespective of thienopyridine use."

http://circ.ahajournals.org/content/132/20/1871.abstract

Wednesday, November 25, 2015

BMJ - "Development and validation of risk prediction equations to estimate future risk of blindness and lower limb amputation in patients with diabetes: cohort study"

 "Development and validation of risk prediction equations to estimate future risk of blindness and lower limb amputation in patients with diabetes: cohort study"

"What this study adds Patients with type 1 or type 2 diabetes are at increased risk of blindness and amputation but generally do not have accurate assessments of the magnitude of their individual risks. The new algorithms calculate the absolute risk of developing these complications over a 10 year period in patients with diabetes, taking account of their individual risk factors."

http://www.bmj.com/content/351/bmj.h5441 

Tuesday, November 24, 2015

NEJM - "Polymer-free Drug-Coated Coronary Stents in Patients at High Bleeding Risk"

"Polymer-free Drug-Coated Coronary Stents in Patients at High Bleeding Risk"

"CONCLUSIONS
Among patients at high risk for bleeding who underwent PCI, a polymer-free umirolimus-coated stent was superior to a bare-metal stent with respect to the primary safety and efficacy end points when used with a 1-month course of dual antiplatelet therapy. (Funded by Biosensors Europe; LEADERS FREE ClinicalTrials.gov number,NCT01623180.)" 

http://www.nejm.org/doi/full/10.1056/NEJMoa1503943

Monday, November 23, 2015

JAMA - "Prostate Cancer Incidence and PSA Testing Patterns in Relation to USPSTF Screening Recommendations"

"Prostate Cancer Incidence and PSA Testing Patterns in Relation to USPSTF Screening Recommendations"

"Conclusions and Relevance  Both the incidence of early-stage prostate cancer and rates of PSA screening have declined and coincide with 2012 USPSTF recommendation to omit PSA screening from routine primary care for men. Longer follow-up is needed to see whether these decreases are associated with trends in mortality."

http://jama.jamanetwork.com/article.aspx?articleid=2470446

Thursday, November 19, 2015

CIRC - "Relation of Smoking With Total Mortality and Cardiovascular Events Among Patients With Diabetes Mellitus"

"Relation of Smoking With Total Mortality and Cardiovascular Events Among Patients With Diabetes Mellitus"

"Conclusions—Active smoking is associated with significantly increased risks of total mortality and cardiovascular events among diabetic patients, whereas smoking cessation is associated with reduced risks in comparison with current smoking. The findings provide strong evidence for the recommendation of quitting smoking among diabetic patients."

http://circ.ahajournals.org/content/132/19/1795.full

Wednesday, November 18, 2015

BMJ - "Computerised cognitive behaviour therapy (cCBT) as treatment for depression in primary care (REEACT trial): large scale pragmatic randomised controlled trial"

"Computerised cognitive behaviour therapy (cCBT) as treatment for depression in primary care (REEACT trial): large scale pragmatic randomised controlled trial"

"What this study adds Supported cCBT does not substantially improve depression outcomes compared with usual GP care alone. In this study, neither a commercially available nor free to use computerised CBT intervention was superior to usual GP care."

http://www.bmj.com/content/351/bmj.h5627 

Tuesday, November 17, 2015

NEJM - "Effect of PCI on Long-Term Survival in Patients with Stable Ischemic Heart Disease"

"Effect of PCI on Long-Term Survival in Patients with Stable Ischemic Heart Disease"

"CONCLUSIONS

During an extended-follow-up of up to 15 years, we did not find a difference in survival between an initial strategy of PCI plus medical therapy and medical therapy alone in patients with stable ischemic heart disease. (Funded by the VA Cooperative Studies Program and others; COURAGE ClinicalTrials.gov number, NCT00007657.)"
http://www.nejm.org/doi/full/10.1056/NEJMoa1505532

Monday, November 16, 2015

JAMA - "Endovascular Thrombectomy for Acute Ischemic Stroke A Meta-analysis"

"Endovascular Thrombectomy for Acute Ischemic Stroke A Meta-analysis"

"Conclusions and Relevance  Among patients with acute ischemic stroke, endovascular therapy with mechanical thrombectomy vs standard medical care with tPA was associated with improved functional outcomes and higher rates of angiographic revascularization, but no significant difference in symptomatic intracranial hemorrhage or all-cause mortality at 90 days."   

http://jama.jamanetwork.com/article.aspx?articleid=2467553

Thursday, November 12, 2015

CIRC - "Dose–Response Relationship Between Physical Activity and Risk of Heart Failure A Meta-Analysis"

"Dose–Response Relationship Between Physical Activity and Risk of Heart Failure A Meta-Analysis"

"Conclusions—There is an inverse dose–response relationship between PA and HF risk. Doses of PA in excess of the guideline-recommended minimum PA levels may be required for more substantial reductions in HF risk."

http://circ.ahajournals.org/content/132/19/1786.full

Wednesday, November 11, 2015

BMJ - "Physician spending and subsequent risk of malpractice claims: observational study"

"Physician spending and subsequent risk of malpractice claims: observational study"

"What this study adds Within specialty and after adjustment for patient characteristics, higher resource use by physicians is associated with fewer malpractice claims."

http://www.bmj.com/content/351/bmj.h5516-0 

Tuesday, November 10, 2015

NEJM - "Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma"

 "Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma"

"CONCLUSIONS
Among patients with previously treated advanced renal-cell carcinoma, overall survival was longer and fewer grade 3 or 4 adverse events occurred with nivolumab than with everolimus. (Funded by Bristol-Myers Squibb; CheckMate 025 ClinicalTrials.gov number,NCT01668784.)"   
http://www.nejm.org/doi/full/10.1056/NEJMoa1510665

Monday, November 9, 2015

JAMA "Trends in Prescription Drug Use Among Adults in the United States From 1999-2012"

"Trends in Prescription Drug Use Among Adults in the United States From 1999-2012"

"Conclusions and Relevance  In this nationally representative survey, significant increases in overall prescription drug use and polypharmacy were observed. These increases persisted after accounting for changes in the age distribution of the population. The prevalence of prescription drug use increased in the majority of, but not all, drug classes."
http://jama.jamanetwork.com/article.aspx?articleid=2467552

Thursday, November 5, 2015

CIRC - "Use of the Wearable Cardioverter Defibrillator in High-Risk Cardiac Patients"

CIRC - "Use of the Wearable Cardioverter Defibrillator in High-Risk Cardiac Patients"

"Conclusions—The WEARIT-II Registry demonstrates a high rate of sustained ventricular tachyarrhythmias at 3 months in at-risk patients who are not eligible for an implantable cardioverter defibrillator, and suggests that the WCD can be safely used to protect patients during this period of risk assessment."

http://circ.ahajournals.org/content/132/17/1613.abstract 

Wednesday, November 4, 2015

BMJ - "Liraglutide in people treated for type 2 diabetes with multiple daily insulin injections: randomised clinical trial (MDI Liraglutide trial)"

BMJ - "Liraglutide in people treated for type 2 diabetes with multiple daily insulin injections: randomised clinical trial (MDI Liraglutide trial)"

"What this study adds Adding liraglutide to multiple daily insulin injections in people with type 2 diabetes improves glycaemic control without an increased risk of hypoglycaemia, reduces body weight, and enables patients to lower their insulin doses."

http://www.bmj.com/content/351/bmj.h5364 

Tuesday, November 3, 2015

NEJM - "A Phase 3 Randomized Trial of Nicotinamide for Skin-Cancer Chemoprevention"

NEJM  - "A Phase 3 Randomized Trial of Nicotinamide for Skin-Cancer Chemoprevention"

"CONCLUSIONS

Oral nicotinamide was safe and effective in reducing the rates of new nonmelanoma skin cancers and actinic keratoses in high-risk patients. (Funded by the National Health and Medical Research Council; ONTRAC Australian New Zealand Clinical Trials Registry number, ACTRN12612000625875.)"  
http://www.nejm.org/doi/full/10.1056/NEJMoa1506197 

Monday, November 2, 2015

JAMA - "Effect of a Buffered Crystalloid Solution vs Saline on Acute Kidney Injury Among Patients in the Intensive Care Unit The SPLIT Randomized Clinical Trial"

JAMA - "Effect of a Buffered Crystalloid Solution vs Saline on Acute Kidney Injury Among Patients in the Intensive Care Unit The SPLIT Randomized Clinical Trial"

"Conclusions and Relevance  Among patients receiving crystalloid fluid therapy in the ICU, use of a buffered crystalloid compared with saline did not reduce the risk of AKI. Further large randomized clinical trials are needed to assess efficacy in higher-risk populations and to measure clinical outcomes such as mortality."
http://jama.jamanetwork.com/article.aspx?articleid=2454911